-

IQVIA’s Nancy Dreyer and Deepa Desai Honored with 2020 PharmaVOICE Awards

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE: IQV) today announced that Nancy Dreyer, chief scientific officer and senior vice president, Real World Solutions, has been awarded PharmaVOICE magazine’s Red Jacket honor after she was recognized multiple times as a PharmaVOICE 100. IQVIA’s Deepa Desai, vice president and head, Quality Management Systems, Quality Assurance, was honored on the 2020 PharmaVOICE 100 List, which identifies the most influential and inspiring leaders within the life sciences industry.

“Congratulations to Nancy and Deepa for receiving these greatly deserved honors,” said IQVIA CEO and Chairman Ari Bousbib. “We are proud of their impactful accomplishments. These awards speak to their strong leadership, vision and strategic abilities to continue to create lasting change within the life sciences industry.”

Nancy Dreyer has been at the forefront of the effort to drive adoption of real world evidence for more than 20 years, making her a pioneer in this space. As a collaborative and transformational leader, Dreyer has driven innovative models for studying safety and effectiveness. She worked with the European Medicines Agency to develop new methods of pharmacovigilance and created the GRACE Checklist, the only validated checklist for measuring the quality of observational studies of comparative effectiveness.

Dreyer has led the charge for recognizing when real world evidence data and methods are sufficiently robust to be reliable enough to guide regulators, clinicians, patients and payers, including evidence from non-interventional studies as well as randomized pragmatic trials. Dreyer, who is also a Drug Information Association Fellow and member of DIA's Science and Policy Advisory Council, was nominated for the Red Jacket Award by DIA President and Global Chief Executive Barbara Lopez Kunz.

“As a leader, Nancy challenges the industry to think differently and raises the bar on a daily basis in terms of what it means to be an inspiring leader for her team, IQVIA, certainly the DIA community and for the industry at large,” Lopez Kunz said. “Nancy’s persistent vision of RWE as the future of clinical research and her work to make what was once impossible possible further underscores her place as an inspirational and transformational leader.”

Deepa Desai began her career as a homeopathic physician in Mumbai, India. Desai developed the Company’s Cardiac Safety business into the first ISO-certified global remote cardiac monitoring organization. The IQVIA unit then became the global industry standard for centralized, large-scale, remote cardiac monitoring. As a leader, Desai is focused on fostering an environment of diversity and inclusion and is committed to mentoring colleagues through the Healthcare Businesswomen’s Association India Ambassador program she launched.

“Deepa has succeeded in leading IQVIA’s Core Clinical Global Delivery Network and Quality Departments, continuously expanding her remit of operation and influence and being on the front lines of transformational change within IQVIA,” said Jeffrey Spaeder, chief medical and scientific officer, Research & Development Solutions at IQVIA. “Deepa fosters a data-driven, solution-oriented culture that enables Quality Assurance to be a valued and impactful business-partner for internal and external stakeholders. We are so proud of her accomplishment.”

The annual PharmaVOICE Red Jacket Award and 100 list celebrates leaders throughout the life sciences industry who provide inspiration through their innovative and motivational approaches to addressing industry challenges. To read the PharmaVOICE profiles, visit http://pharmavoice.com.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies Human Data Science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 67,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Contacts

Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com)
+1.484.567.6732

Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com)
+1.973.257.7144

IQVIA

NYSE:IQV
Details
Headquarters: Durham, NC, NC
Website: www.iqvia.com
CEO: Ari Bousbib
Employees: 87,000
Organization: OTH
Revenues: $14.4 B (service rev) (2022)

Release Versions

Contacts

Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com)
+1.484.567.6732

Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com)
+1.973.257.7144

More News From IQVIA

IQVIA to Provide Sanofi Its Orchestrated Customer Engagement (OCE) Platform in Africa & Middle East

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry, today announced that Sanofi will use the IQVIA OCE platform in select countries across Africa and the Middle East. IQVIA OCE is a next-generation life sciences commercial platform that connects all customer-facing functions to deliver more personalized and optimized custome...

IQVIA and CEPI Collaborate to Strengthen Global Research Preparedness to Advance the 100 Days Mission

RESEARCH TRIANGLE PARK, N.C. & OSLO, Norway--(BUSINESS WIRE)--IQVIA, (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services, and The Coalition for Epidemic Preparedness Innovations (CEPI) today announced a strategic collaboration to advance the 100 Days Mission. In conjunction with national and regional collaborators, CEPI and IQVIA will aim to enhance the world’s preparedness to rapidly conduct life-saving clinical research for vaccine...

IQVIA to Announce Third-Quarter 2023 Results on November 1, 2023

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its third-quarter 2023 financial results before the market opens on Wednesday, November 1, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentati...
Back to Newsroom